Tuesday, September 19, 2024
12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET
Register
In May 2022, mpox infections were seen in Europe and the Americas, with eventually 110 countries reporting 87,000 cases and 112 deaths. On July 23, 2022 the World Health Organization (WHO) declared mpox a public health emergency of international concern (PHEIC). Specifically in the United States, greater than 31,000 cases were seen, with 57 deaths.
Mpox belongs to the orthopoxvirus genus and is spread by close contact. Symptoms include skin rashes or mucosal lesions, fever, headache, myalgias, fatigue and swollen lymph nodes. In rare cases, the disease can lead to death. Most of the mpox cases in 2022/23 were identified among gay, bisexual and other men who have sex with men (MSM). Additional risk factors may include close contact with people with mpox infections or prolonged contact with contaminated objects (clothing, bedding, towels, etc.).
In August 2023, the Centers for Disease Control and Prevention (CDC) recommended a 2-dose mpox vaccine for people with exposure to mpox, had recent (2 weeks) sex with a partner diagnosed with mpox, are a gay/bisexual/MSM, and/or engage in sex at large venues within the past 6 months. The vaccine can be given as a subcutaneous or intradermal injection, with the administration volume differing based on technique. As most vaccines are administered intramuscularly, healthcare professionals, including pharmacists, may not be familiar with these administration techniques.
The goal of this educational webinar is to provide information to pharmacists and other healthcare providers on Mpox vaccine. The webinar will include a presentation by an expert faculty, active learning engagement questions throughout, and a live question & answer session.
Target Audience:
This activity was planned to meet the educational needs of infectious diseases pharmacists. The educational content is also relevant for other healthcare providers involved in mpox vaccine recommendation and administration.
Learning Objectives:
- Describe the epidemiology and clinical presentation of mpox.
- Evaluate clinical data demonstrating efficacy of mpox vaccination.
- Identify patient populations at risk of mpox and who should receive vaccination.
- Review vaccination best practices: the preparation and administration of mpox vaccine and pharmacist driven vaccination programs.
Faculty:
Rodrigo M Burgos, PharmD, MPH
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois Chicago
Chicago, IL
Accreditation:
Pharmacist
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0672-0000-24-024-L06-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Knowledge
Activity Fee: Free
To receive CE credit, participants must attend the webinar, complete online a post-test with a passing score of 70% or greater and an activity evaluation. Proof of completion will be submitted to NABP CPE Monitor.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.
Funding:
This webinar is supported by an unrestricted educational grant from Bavarian Nordic.
Disclosures:
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:
- Dr. Burgos has received research funding from ViiV Healthcare/GSK, Merck & Co., Inc, Moderna, Inc, Janssen Vaccines & Therapeutics, Shionogi & Co. Ltd, and served as a consultant/advisor/speaker for ViiV Healthcare/GSK.
- SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.
Disclaimer:
Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.
The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.
Register
.gif){kind=logo}